GlassScriptPhysician profile
Brian P Miller
NPI 1861411381
$146,465.24
in general payments reported to CMS, 2019-2025
17 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $11K · 2021: $12K · 2022: $30K · 2023: $22K · 2024: $25K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Consulting Fee: $9,691 · Food and Beverage: $5,230 · Travel and Lodging: $3,579 · Honoraria: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,027.00 |
| Consulting Fee | $9,691.25 |
| Food and Beverage | $5,229.91 |
| Travel and Lodging | $3,578.90 |
| Honoraria | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $128,716.47 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $4,987.69 | 2019-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $4,385.86 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,148.37 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $3,143.24 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $420.73 | 2019-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $371.19 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $279.10 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $279.03 | 2019-2025 | Fanapt |
| Livanova USA, INC. | $186.01 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| H2-Pharma, LLC | $150.00 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $129.04 | 2019-2025 | Uzedy |
| Lundbeck LLC | $94.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $54.22 | 2020-2025 | Nucala, Trelegy Ellipta |
| Indivior INC. | $53.44 | 2024-2025 | Perseris, Sublocade |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $49.93 | 2023 | Igalmi |
| Arbor Pharmaceuticals, INC. | $16.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.